tiprankstipranks
Anika Therapeutics Refocuses on Core Technology and Growth
Company Announcements

Anika Therapeutics Refocuses on Core Technology and Growth

Don't Miss our Black Friday Offers:

Anika Therapeutics ( (ANIK) ) has provided an announcement.

Anika Therapeutics has strategically shifted its focus by divesting Arthrosurface and planning to sell Parcus Medical, aiming to concentrate on its core hyaluronic acid technology and expanding Regenerative Solutions portfolio. The sale of Arthrosurface to Phoenix Brio was completed for $10 million, including a promissory note and potential sales-based consideration. Anika’s efforts are part of a broader strategy to streamline operations and enhance growth in the orthopedic market, estimated at $4 billion globally.

See more data about ANIK stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAnika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts
TheFlyAnika Therapeutics price target lowered to $25 from $37 at Barrington
TipRanks Auto-Generated NewsdeskAnika Therapeutics Focuses on Core Growth Amid Restructuring
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App